The New York TimesJan 14, 2021 13:34:50 IST
Scientists in Brazil have downgraded the efficacy of a Chinese coronavirus vaccine that they hailed as a major triumph last week, diminishing hopes for a shot that could be quickly produced and easily distributed to help the developing world. Officials at the Butantan Institute in São Paulo said Tuesday that a trial conducted in Brazil showed that the CoronaVac vaccine, manufactured by the Beijing-based company Sinovac, had an efficacy rate just over 50%. That rate, slightly above the benchmark that the World Health Organization has said would make a vaccine effective for general use, was far below the 78% level announced last week.
The implications could be significant for a vaccine that is crucial to China’s global health diplomacy. At least 10 countries have ordered more than 380 million doses of the Sinovac inoculation, CoronaVac, although regulatory agencies have yet to fully approve it.
A senior official in Hong Kong, a special administrative region of China that had already ordered CoronaVac, said Wednesday that an advisory panel would strictly review the vaccine based on clinical trial data before it was rolled out there.
“Those countries that have ordered the Chinese-made vaccines are probably going to question the usefulness of these vaccines,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations and an expert on health care in China.
“Countries with opposition parties might use this to challenge the decision made by the incumbent government, and that will likely have domestic political implications in these countries,” Huang said.
Sinovac did not respond to multiple requests for comment.
For months, Chinese officials had said that the vaccines made by Sinovac and Sinopharm, a state-owned vaccine maker, would be important tools for fighting the pandemic in poorer countries that do not have extensive health care infrastructures. Unlike the vaccines made by U.S. drugmakers Pfizer and Moderna, they do not need to be frozen.
The Oxford-AstraZeneca and Johnson & Johnson vaccines, which can be kept refrigerated and are more effective than their Chinese counterparts, could provide an alternative. But it is now unclear if the governments that have bought CoronaVac can scrap their deals and turn to others.
CoronaVac, unlike some of the other vaccines, relies on older technology that uses chemicals to weaken or kill the virus, which is then put into a vaccine to spark antibodies in the recipient. But the process of killing the virus can weaken a vaccine’s potency, resulting in an immune response that could be shorter or less effective.
The lower efficacy announced Tuesday would mean it would take longer for countries that use CoronaVac’s vaccine to reach “herd immunity,” the point at which enough people are resistant to the virus — roughly 70%, many scientists have said — that it is vanquished in a population. By contrast, the vaccines made by Moderna and Pfizer-BioNTech have been shown to have an efficacy rate of about 95%.
“This was one of the reasons the Americans and Europeans didn’t go with this older technology,” said John Moore, a vaccine expert at Cornell University. “A well-maintained Ford Model T would probably get you from Wuhan to Beijing, but personally I would prefer a Tesla.”
Brazil’s health regulatory agency, Anvisa, is reviewing data from the trial, which relied on volunteers who are health care professionals. If Anvisa approves emergency use of CoronaVac, officials hope to start giving out shots in Brazil late this month. It has roughly 10.8 million doses of CoronaVac on hand. Last week, Brazil’s health minister, Eduardo Pazuello, said the government intended to purchase 100 million doses of CoronaVac.
Natalia Pasternak, a microbiologist and the president of Instituto Questão de Ciência, a Brazilian nongovernmental organization, told reporters Tuesday that the results of the trial meant it would not be a panacea.
“It is not the best vaccine in the world,” she said at the news conference during which the efficacy rate was disclosed. But she called it a “perfectly acceptable vaccine” that would lead to fewer patients developing serious cases or dying from the virus.
Dimas Covas, the director of Butantan Institute, called the vaccine an “excellent” tool “waiting to be used in a country where currently 1,000 people are dying per day.”
Many of the countries that have ordered CoronaVac are relatively poor, desperate to halt the pandemic and protect their populations.
Indonesia, for example, has ordered 125.5 million CoronaVac doses. The country has reported nearly 850,000 coronavirus cases and nearly 25,000 deaths, the highest numbers in Southeast Asia.
On Wednesday morning, its president, Joko Widodo, was injected with CoronaVac on live television, kicking off a national vaccination program.
“COVID vaccination is important for us to break the chain of transmission of this coronavirus and provide health protection for all of us,” Joko said after getting his shot.
Sulfikar Amir, an Indonesian associate professor of disaster sociology at Nanyang Technological University in Singapore, said the latest results from Brazil were a cause for concern.
“Why doesn’t Indonesia wait for a better vaccine?” he asked. “My impression is that this is rushed and forced.”
In the short term, some countries may have few viable vaccine options. Governments, many of them in richer nations, have already locked in more than half the doses that could come onto the market by the end of next year.
To its comparative advantage, Sinovac has immense manufacturing capacity. The company has said it can make 600 million doses this year.
In China, the weaker efficacy data from Brazil could be a setback for the country’s biotech ambitions. It had pinned its hopes on making a COVID-19 vaccine that would burnish its credentials as a global scientific power.
The tepid results could also be problematic for Chinese officials, given that they had touted the efficacy of the vaccines made by Sinovac and Sinopharm. Even though the vaccines had not received regulatory approval, and data from late-stage trials had not been made public, Beijing gave them to thousands of Chinese people under an emergency use policy; it plans to vaccinate 50 million people by the middle of next month.
State media in China played down the news from Brazil. Global Times, a state-owned nationalist tabloid, ran a headline that said the Sinovac vaccine was “100% effective in preventing severe cases, could reduce hospitalizations by 80%.”
The new data could heighten skepticism among people around the world who are already wary of Chinese-made vaccines, given that the country has a history of vaccine quality scandals. A study from the Chinese University of Hong Kong found that just 37.2% of respondents in Hong Kong were willing to be vaccinated.
Scientists had already raised questions about the piecemeal way in which efficacy data about the Chinese vaccines had been released. Indonesia said Monday that its interim analysis found CoronaVac to have an efficacy rate of 65.3%. Last month, Turkey said it had an efficacy rate of 91.25%, but that was based on preliminary results from a small clinical trial.
The vaccine had long taken on a political dimension in Brazil. President Jair Bolsonaro had spoken derisively about CoronaVac, fueling an growing anti-vaccination movement in the country, where more than 200,000 people have died from COVID-19. The vaccine had been championed by Sao Paulo’s governor, João Doria, who is widely expected to run for president in 2022 and is among Bolsonaro’s most vocal critics.
In Brazil, officials say the higher efficacy rate previously announced for CoronaVac pertained to the protection it offered against developing COVID-19 symptoms significant enough to require treatment. While officials had asserted last week that the vaccine provided absolute protection against moderate to severe symptoms, they had not disclosed another group who had “very mild” infections despite having been vaccinated.
Denise Garrett, a Brazilian-American public health researcher and vaccine expert, said there was no reason to doubt CoronaVac’s safety, adding that the data presented so far suggested it would provide a satisfactory level of protection. But Garrett said the vague and sometimes misleading manner in which information about the vaccine had been made public could shake people’s confidence in its reliability and fuel the political battle over the vaccine.
“The lack of transparency really damages people’s trust,” she said. “They’ve just reinforced the narrative that this vaccine is not good.”
Sui-Lee Wee and Ernesto Londoño. c.2021 The New York Times Company